Twist Bioscience, Eleven Therapeutics Create Synthetic Viral RNA Molecules To Develop Antiviral Vaccines,

Twist Bioscience Corp (NASDAQ:TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication, antiviral drug screening, and vaccine & therapeutic development.

Replicons are synthetic viral RNA molecules that mimic viruses in their ability to replicate but have been engineered to remove the portion of the genome that causes harm (infectiousness).
Replicon systems have been used to mimic RNA viruses including Zika, Dengue, and SARS-CoV-1 to facilitate therapeutics' safe and rapid development.
Also See: Twist Bioscience Clocks ~50% Jump In Q1 Sales, Lifts FY22 Revenue Guidance.
Through a publication on bioRxiv, the teams demonstrated the development of a safe and efficient SARS-CoV-2 replicon-generating engine.
The teams retained 97% of the viral genome but eliminated any infectivity properties of SARS-CoV-2.
Researchers can use this replicon to study viral activity without patient samples or the risk of handling live viruses.
Price Action: TWST shares are trading 6.08% higher at $63.12 during the market session on the last check Monday.

TWSTTwist Bioscience Corp

$55.95-%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

Benzinga

Benzinga

Twist Bioscience, Eleven Therapeutics Create Synthetic Viral RNA Molecules To Develop Antiviral Vaccines, Therapeutics